Microbot Medical Secures First International Regulatory Approval for LIBERTY Robotic System in Israel
MBOT is trading near its 52-week low of $1.6 (8.1% above the low).
Summary
Microbot Medical Inc. has received regulatory approval from the Israeli Ministry of Health for its LIBERTY Endovascular Robotic System, marking its first international market clearance. This approval enables commercialization in Israel and supports further global expansion efforts.
Key Events · Product Development and Regulatory · MBOT
-
First International Regulatory Approval
Microbot Medical received regulatory approval from the Israeli Ministry of Health's AMAR Division for its LIBERTY Endovascular Robotic System. This marks the first international market clearance for the system outside of the U.S.
-
Enables Global Expansion
The approval allows the company to market and commercialize the LIBERTY System in Israel and facilitates obtaining a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
-
Builds on U.S. Momentum
This milestone follows the successful launch and adoption of the LIBERTY System in multiple accounts and hospitals across several U.S. states, and the company continues to pursue CE Mark certification for future EU expansion.
Analysis · MBOT · Industrial Applications And Services
This regulatory approval in Israel is a significant step for Microbot Medical, marking its first international market clearance for the LIBERTY Endovascular Robotic System. It validates the product for global markets, opens a new revenue stream, and streamlines future approvals in other jurisdictions by enabling the company to obtain a Free Sale Certificate. This builds on the recent commercial momentum and successful launch of the LIBERTY system in the U.S., indicating progress in the company's global expansion strategy.
At the time of this filing, MBOT was trading at $1.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $114.9M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.